Product Images Oxcarbazepine

This is a bottle of Oxcarbazepine tablets containing 100 pills each with 150mg strength of the drug. It should be stored at room temperature between 20-25°C (68-77°F) and away from children. It's advised to see the package insert for usage directions. The bottle was repackaged by RemedyRepack Inc. in Indiana, USA. There is also a lot number, NDC number and expiry date mentioned.*

OXcarbazepine is a tablet medication with a strength of 150mg, which is packaged by RemedyRepack Inc. The medicine is available only by prescription and its National Drug Code (NDC) number is 70518-0894-02. The NDC number can be used to locate the source NDC, which is 51991-0292-01. The medication should be kept at a temperature range of 20-25°C and away from children. For usage guidelines, refer to the package insert. The expiration date and lot number are not available, and the drug is manufactured by Breckenridge in Boca Raton, FL 33487.*

This is a prescription drug called Oxcarbazepine, in tablet form and a package containing 30 tablets each of 150 mg. The medication is manufactured by Breckenridge and repackaged by RemedyRepack Inc. The National Drug Code (NDC) number is 70518-0894-00, and the lot number and expiry date are not available. There are directions to store the medication at a temperature between 20-25°C (58-77°F). A package insert is available with the package. The label advises keeping the medication out of the reach of children.*

This appears to be a graph displaying the exit rate and log-rank test results for a trial involving a placebo. It shows the exit rate decreasing over time and includes data from day 2 to day 11. The p-value for the log-rank test is 0.0001.*

This text presents statistical analysis results of a drug (Oxcarbazepine) for the treatment of seizures. The log-rank test indicates a p-value of 0.046, which suggests a significant difference between drug treatment and placebo. The chart shows the number of days from the first dose of the drug to the first seizure for both the treatment group and the placebo group.*

This is a result of a log-rank test with a p-value of 0.0001 showing time to exit in days for a treatment group with high and low values. There are also some seemingly irrelevant characters and numbers present.*

This is a survival analysis report where Exit rate was analysed between groups of different treatments. The log-rank test was performed, and a p-value of 0.0001 was obtained, indicating a significant difference between the treatment groups. The time to exit was recorded in days between 0 and 130. The treatment groups were labeled as HIGH and LOW.*